Search results (1751)
« Back to PublicationsMyeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.
Conference paper
Gagnon LL. et al, (2026), Leukemia
MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.
Journal article
Lau I-J. et al, (2026), Blood
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.
Journal article
Beernaert B. et al, (2026), Sci Adv, 12
Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).
Journal article
Papayannidis C. et al, (2026), Oncol Ther
comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.
Journal article
Shen Y. et al, (2026), Cell Stem Cell, 33, 421 - 437.e7
Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.
Journal article
Makker J. et al, (2026), Haematologica, 111, 1096 - 1099
JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.
Journal article
Kealy D. et al, (2026), Leukemia, 40, 609 - 621
Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.
Journal article
Palandri F. et al, (2026), Clin Lymphoma Myeloma Leuk
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.
Journal article
Turkalj S. et al, (2026), Blood, 147, 613 - 632
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline.
Journal article
Godfrey AL. et al, (2026), Br J Haematol, 208, 471 - 485
The circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validation.
Journal article
Dillman A. et al, (2026), EBioMedicine, 124
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.
Journal article
O'Sullivan J. et al, (2026), Br J Haematol, 208, 437 - 441
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology.
Journal article
Phillips R. et al, (2026), Br J Cancer, 134, 289 - 294
Correction: Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.
Journal article
Buckell J. et al, (2026), Br J Cancer, 134, 175 - 176